About 7 results found for searched term "AP102" (0.129 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6579 | Cerestat | Others |
| Aptiganel; CNS-1102 | ||
| Cerestat (also known as Aptiganel, CNS-1102) is a potent and noncompetitive NMDA receptor antagonist. | ||
| M41943 | AP102 | Somatostatin Receptor |
| AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). | ||
| M9692 | IAXO-102 | TLR |
| Iaxo-102 is an antagonist of TLR4 and inhibits the TLR4 signaling pathway. Iaxo-102 inhibits phosphorylation of MAPK and P65 NF-KB and expression of TLR4 and TLR4-dependent inflammatory proteins. Iaxo-102 inhibits the development of experimental abdominal aortic aneurysms. | ||
| M24546 | Timolumab | Others |
| BTT 1023; Anti-Human AOC3 Recombinant Antibody | ||
| Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases. | ||
| M28058 | MS-1020 | JAK |
| MS-1020 is a potent and ATP-competitive JAK3 inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling. | ||
| M28214 | UNC10217938A | Others |
| UNC10217938A is a 3-deazapteridine analog with strong oligonucleotide enhancing effects. UNC10217938A enhances oligonucleotides effects by modulating their intracellular trafficking and release from endosomes. UNC10217938A also enhances the effects of antisense and siRNA oligonucleotides. | ||
| M30897 | Reproxalap | RASP |
| ADX-102; NS-2 | ||
| Reproxalap (ADX-102) is a reactive aldehyde species (RASP) sequestering agent for the treatment of dry eye. Reproxalap (ADX-102) covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
